UNSPSC 51183603: Insulin

This classification denotes a therapeutic insulin with the molecular formula C256H381N65O79S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D933668QVX, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG.

UNSPSC 51183603 Insulin is a Commodity code covering insulin products procured by state and local health and human services agencies, Medicaid programs, and public health systems. State and local governments buy insulin through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and establish master contracts with pharmaceutical manufacturers and wholesalers. Work under this code involves supplying insulin products with specific National Drug Codes (NDCs) and packaging configurations, meeting FDA compliance and Good Manufacturing Practice (cGMP) certification requirements, maintaining expiration dates and shelf-life standards, and integrating with authorized pharmaceutical wholesaler networks through chargeback systems and electronic data interchange (EDI) capabilities. Issuing bodies include state pharmacy benefit managers, state Medicaid agencies, and multistate cooperative purchasing alliances that coordinate procurement on behalf of participating state and local government facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the most recent major activity under this code. MMCAP issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products, including insulin, for distribution across participating state and local government facilities in Minnesota and Oregon. The procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and awards will be effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent) and flexibility in pricing structures (flat price, net price formats, or WAC-minus); vendors must maintain comprehensive insurance including commercial general liability of $5,000,000 per occurrence and comply with performance standards enforced through penalties ranging from $200 to $1,500 per violation. The contract term is two years for new responders with optional extensions, or alignment with existing agreement expiration dates through June 30, 2028 for incumbent vendors.